Literature DB >> 23040967

What really happens to tuberculosis patients classified as lost to follow-up in West Yorkshire?

M Day1, A Middlemiss, J Thorpe, E Okereke.   

Abstract

Tuberculosis (TB) patients who do not complete treatment pose a potential public health risk. In West Yorkshire, local clinicians suspected that this risk was overestimated by the national Enhanced Tuberculosis Surveillance system. We audited patients who failed to complete treatment and were categorised as lost-to-follow-up (LTFU) between 2004 and 2008, using a combination of hand searching existing records and obtaining additional information from clinicians. In the study period 2,031 TB cases with reported outcome were notified in West Yorkshire, 23% (n=474) did not complete treatment, and 199 (42%) of those were categorised as LTFU 12 months after notification. Of these 199, 49% (n=98) remained LTFU after the audit, 51% (n=101) were re-classified to the following categories: 24% (n=47) transferred abroad, 16% (n=31) recommenced and completed treatment, 6% (n=13) transferred to another clinic in the United Kingdom (UK), and 5% (n=10) died. These patients therefore no-longer posed a public health risk. Further training for clinicians to improve accuracy of outcome reporting has been initiated. Nationally, the collection of treatment outcome data needs to be strengthened and extending the follow-up for treatment outcome monitoring should be considered.

Entities:  

Mesh:

Year:  2012        PMID: 23040967

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  4 in total

Review 1.  Transfer of primary care patients receiving chronic care: the next step in the continuum of care.

Authors:  Jasantha Odayar; Landon Myer
Journal:  Int Health       Date:  2019-11-13       Impact factor: 2.473

2.  Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.

Authors:  Lara J Wolfson; Anna Walker; Robert Hettle; Xiaoyan Lu; Chrispin Kambili; Andrew Murungi; Gerhart Knerer
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

Review 4.  Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014.

Authors:  Inge K Holden; Peter H Andersen; Christian Wejse; Troels Lillebaek; Isik S Johansen
Journal:  BMC Health Serv Res       Date:  2020-02-03       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.